MedWatch

Fund chief to kickstart fundamental changes in antibiotics market

Even though Novo Nordisk-funded AMR Action Fund was created to finance the development of antibiotics, CEO Henry Skinner expects that a lot of the fund's work will also involve raising awareness on the deepening lack of new antibiotics.

AMR Action Fund Henry Skinner | Photo: AMR Action Fund / PR

Henry Skinner struggles to hold himself back when discussing current issues with the antibiotics market. As the newly appointed CEO for the antimicrobial resistance research fund AMR Action Fund, being passionate about this area is sort of embedded in his job description.

The fund was established last year by a confederation of some of the world's largest pharmaceutical companies, with Novo Nordisk being one of the major contributors. The underlying purpose is to support the failing antibiotics market, which is generating ever-fewer new drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs